Evolus (EOLS) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Evolus (EOLS) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 24.1% versus a loss of 21.8%. Over five years, MNPR leads with a +221.6% price change compared with +0.8% for EOLS. Monopar Therapeutics is the larger company by market cap ($530.0 million vs $510.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | MNPR |
|---|---|---|
| Share price | $7.73 | $78.96 |
| Market cap | $510.57M | $529.99M |
| 1-day change | -0.90% | -5.98% |
| YTD return | +16.24% | +20.92% |
| 1-year return | +24.08% | -21.79% |
| 5-year return | +0.78% | +221.63% |
| Forward P/E | 26.43 | — |
| EPS (TTM) | $-0.53 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $124.82 |
| 52-week low | $3.86 | $50.07 |
| Distance from 52-week high | -16.97% | -36.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +94.05% | +64.54% |
| Average volume | 904.95K | 213.15K |
| Shares outstanding | 66.05M | 6.71M |
| Employees | 353 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed MNPR by 45.9 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
EOLS vs MNPR FAQ
Which is bigger, Evolus or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $529.99M compared with $510.57M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or MNPR?
EOLS returned +24.08% over the past 12 months, compared with -21.79% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.